What Twenty Years of “Borderline” Blood Pressure Actually Costs You

In the emergency department, when someone is sick enough, we stop treating blood pressure as a single number. We thread a thin catheter into an artery, an arterial line, and the monitor draws the pressure out continuously, beat after beat. It climbs with pain. It drops after sedation. It swings with every fluid bolus and every breath. That is blood pressure as the artery actually lives it: not a reading, a moving signal.

Almost no one healthy ever sees their blood pressure that way. They get the opposite, one rushed cuff reading at a yearly physical, after the coffee and the traffic and ten minutes in a bright waiting room. The number gets a label, fine or borderline or high, and the conversation moves on. It is a little like judging your blood sugar from a single random fingerstick once a year and pretending you understand the curve. Keep that gap in mind, the continuous signal against the once-a-year sample, because it turns out to be the whole story.

Imagine a 35-year-old whose blood pressure reads 132/85 at their annual physical. Their physician glances at the number and calls it “borderline.” Maybe a vague suggestion to cut back on salt, lose a few pounds, recheck in a year. Nothing in the conversation feels alarming.

Now imagine that same person, twenty years later, being wheeled into a cath lab with a critical occlusion in their right coronary artery. The plaque didn’t show up overnight. It accumulated, every year, while their blood pressure was “borderline.” The number at 35 didn’t move the conversation. The number at 45 didn’t either. The number at 55 finally did, but by then it was a procedure rather than a prevention. Unfortunately this was me. I didn’t visit the doctor often in my 20s and 30s. I was healthy and rarely got sick, and I skipped most yearly physicals. But I know my blood pressure was never that “perfect” 120/80 or below. It also was never horrible, even though by today’s guidelines I had hypertension.

The numbers behind this aren’t soft. In the largest meta-analysis ever assembled on the topic, pooling individual data from over one million adults across sixty-one cohort studies, the relationship between blood pressure and cardiovascular mortality was continuous and linear all the way down to a systolic of 115 mmHg and a diastolic of 75 mmHg.² From there upward, every additional 20 mmHg systolic or 10 mmHg diastolic roughly doubled the risk of death from heart disease and stroke. No inflection point. No threshold below which it stopped mattering. The artery was logging the damage at every reading, every year, regardless of whether the doctor called the number “borderline” or “fine.”

The problem isn’t that 132/85 is a medical emergency. It almost never is, and the medical system typically doesn’t treat blood pressure as an emergency until it gets up around 180/120. But the damage starts long before that. The standard visit measures blood pressure as a snapshot, treats anything short of stage 2 hypertension as discretionary, and acts as if the years between snapshots don’t count. They do. And the cleanest evidence all points the same way: Mendelian dose-response curves on lifelong exposure, a million-person meta-analysis of cardiovascular cohorts, decades of longitudinal data on cumulative pressure load, and a marquee randomized trial stopped early because the benefit was unmistakable. All of it says the same thing. What’s happening between your readings is doing most of the work.

Last week I walked through the cumulative math of borderline LDL and what twenty years of mildly elevated cholesterol does to an artery wall. This week I want to put borderline blood pressure through the same treatment. The construct is identical. The numbers are different. The arithmetic is the chapter nobody walked through with me.

Because for most of my adult life, from my early thirties through the day I got carted into the cath lab, my blood pressure averaged something like 132 over 85. Sometimes higher on the diastolic side. Not dramatic, not the kind of number that gets you a prescription. Just, as I wrote when I named the cracks I’d dismissed, “not optimal.” I knew what optimal looked like. I had run a hundred blood pressures a shift in the ER. I wrote mine off as white coat effect, or training stress, or just close enough. It was always “close enough.” And twenty years of close enough is not a holding pattern. It’s an unfolding cost, and that cost is the math I want to walk through here, because I should have read it myself fifteen years ago.

---

The Bottom Line A single office blood pressure is a weak sample of a signal that never stops moving. The artery doesn’t experience a number once a year; it absorbs pressure continuously, every beat, for decades. That’s why a reading the system calls “borderline” stops being reassuring the moment you carry it across time: the damage is the running total, not the snapshot.

I’m not saying a 35-year-old at 132/85 needs a pill tomorrow. I’m saying “it’s borderline, we’ll recheck in a year” is an incomplete answer to a problem that unfolds over thirty years. The cheapest cardiovascular intervention I never made was the home-cuff average and the honest conversation I could have had at thirty.

---

Vocabulary that matters

• Systolic pressure: the top number, the push on your artery walls each time the heart beats.
• Diastolic pressure: the bottom number, the pressure that remains while the heart relaxes between beats.
• Stage 1 hypertension: 130/80 or higher, under the current U.S. guideline. The range once waved off as “borderline” is now a named diagnosis.
• mmHg-years: excess pressure above a sensible reference line, multiplied by the years you carry it. Blood pressure’s version of pack-years.
• Arterial line: a catheter placed in an artery that reads blood pressure continuously, beat to beat. How we watch it in the ER, and how the artery actually experiences it.
• Endothelium: the living inner lining of the artery, one cell thick, where pressure does its daily work and where plaque begins.

---

What “borderline” actually means in current practice

For decades, primary-care medicine treated 140/90 as the line. Below it, fine. Above it, hypertension. That worked, more or less, when the ten-year horizon was the only horizon. It does not work anymore.

In August 2025, the American College of Cardiology and the American Heart Association, with eleven other professional societies, published the most consequential update to the U.S. blood pressure guideline since 2017.³ Two changes matter for anyone with a systolic in the 130s.

The first: “borderline” is no longer a clinical category. Anything 130/80 or above is now formally Stage 1 hypertension. Not “elevated,” not “prehypertension.” Stage 1, the same word the framework used to reserve for numbers that triggered a prescription. The threshold didn’t move because anyone changed their mind about biology. It moved because the cumulative-exposure evidence finally got too loud to ignore.

The second is more clinically active. The 2025 guideline replaces the old Pooled Cohort risk equation with a calculator called PREVENT, and it tightens the medication trigger for adults whose 10-year predicted risk is below 7.5%. If your average blood pressure is 130/80 or higher and a three-to-six-month trial of lifestyle change doesn’t bring it under 130/80, the recommendation is now to start medication. The ACC’s own commentary acknowledges this will prescribe more younger patients, because the cumulative exposure starts earlier than the old ten-year score was ever designed to see.

That, in plain terms, is the framework moving toward the math. The thirty-five-year-old at 132/85 isn’t a soft call anymore. They’re a stage-1 hypertensive on a twenty-year clock.

---

The advice that’s supposed to bridge the gap

The standard playbook for stage-1 hypertension still leads with lifestyle, and it should. The right answer for someone at 132/85 is rarely “start medication tomorrow.” Sodium restriction, alcohol moderation, weight loss, physical activity, the DASH eating pattern, treating sleep apnea when it’s present: each can move a borderline number measurably.

But the size of the move is where the framework quietly underperforms the math. The best dietary trials in well-controlled settings produce systolic drops on the order of 5 to 8 mmHg, and real-world adherence over years cuts that further. Even a sustained 5 mmHg reduction is meaningful at the population level. It is also not enough, on its own, to close a 15-to-20 mmHg gap on a dose-response curve that runs down to 115 systolic. The gap is bigger than the lifestyle prescription, as typically delivered, actually closes.

This isn’t an argument against lifestyle. It’s an argument for honesty about what lifestyle alone does and doesn’t do for someone whose true average is in the low 130s. “We’ll watch it” only works if someone is actually watching, and that means the patient and the clinician looking at the same thing: not the snapshot, but the trajectory.

---

Why we measure cigarettes in years and blood pressure in moments

Consider how we talk about a different cumulative exposure. A pack a day for twenty years is twenty pack-years. No physician shrugs at twenty pack-years because the patient happens not to be smoking the morning of the appointment. The cumulative number is the diagnosis. Lung cancer risk, COPD risk, even smoking-attributable heart risk all scale with pack-years, not with whether the patient inhaled in the parking lot. The unit was invented because the moment was misleading and the running total was honest.

Blood pressure works the same way at the cellular level, with one important difference. The artery doesn’t experience a number; it experiences a force, every beat, every year. The endothelial cells lining the vessel wall are mechanically stressed continuously, and the damage they accumulate is a function of pressure times time, not pressure at one office visit. The screening framework just hasn’t absorbed that arithmetic the way it did for smoking.

Here’s the difference, because the analogy isn’t clean. Cigarettes have a defensible zero: no cigarettes, no exposure, no harm. Blood pressure does not. Pressure isn’t bad; it’s necessary. The heart spends every beat producing it to perfuse the brain, the kidneys, and the coronary tree. Drop it low enough and the system fails the other way: syncope, ischemia, organ injury, death. I see the dangers of low blood pressure regularly in the ER. The relationship between blood pressure and harm is J-shaped, not a straight line to zero. So the right metric isn’t the running total of pressure across a lifetime, which would score a dead person at zero. It’s excess blood-pressure years: the running total of pressure above a sensible reference baseline, accumulated across the years you spend above it.

Take 120/80 as the reference, since that’s what most people associate with “normal” and the line above which the 2025 guideline starts calling blood pressure elevated. Honest caveat: the cleanest evidentiary floor in the Lewington data sits closer to 115/75, below which the dose-response simply runs out of cohort data. The exact baseline you pick changes the size of the numbers below but not the direction. Call the unit mmHg-years, or vessel wall exposure above baseline. What matters is that the framework starts taking the running total seriously, the way it already does for cigarettes.

---

What cumulative blood pressure exposure actually measures

Cumulative excess exposure is the area between your actual systolic curve and the 120 reference line, added up across the years you spend above it. Someone whose systolic averages 120 from age 20 to 65 accumulates zero excess mmHg-years; the artery is doing exactly the work it was built for. Someone who averages 134 across the same forty-five years accumulates 14 × 45 = 630 excess mmHg-years, the total “above baseline” load their artery has absorbed every day for forty-five years.

That number doesn’t look enormous in isolation, but it’s an extra fourteen millimeters of mercury pushing on the inside of your arteries, continuously, for forty-five years. Every endothelial cell in your coronary tree, your renal arteries, your cerebral vessels has done its job under a slightly heavier load every minute of every day. That cumulative cellular cost is what the snapshot can’t see.

Illustrative arithmetic across forty-five years. A systolic average of 134 is only 14 mmHg above the 120 reference line, but from age 20 to 65 that becomes 630 excess mmHg-years of exposure. Using 115 instead of 120 changes the size of the number, not the direction of the argument. Schematic, not individual risk prediction.

This isn’t a thought experiment. The major cardiovascular cohorts have begun computing exposure metrics like this directly, adding up each person’s blood-pressure trajectory across decades and asking whether the running total predicts events better than any single measurement. It does. The Lifetime Risk Pooling Project, combining five racially diverse U.S. cohorts followed into middle age, found that higher cumulative systolic exposure predicted both higher event rates and earlier age at first event, after adjusting for whatever the blood pressure happened to be at the moment of measurement.⁶ The CARDIA cohort, which followed young adults from their late teens into their fifties, found cumulative exposure in young adulthood to be a strong predictor of heart failure, coronary disease, and stroke decades later, with hazard ratios that rose steadily with accumulated exposure.⁵ The unit may not be on your lab report yet. The biology has been computing it the whole time.

---

SPRINT: what happens when you actually pull the trigger

If cumulative exposure is the construct, the next question is whether lowering it earlier produces fewer events. That is what SPRINT was built to answer, and the answer was decisive enough that the trial was stopped early on its safety board’s recommendation.¹

SPRINT enrolled 9,361 adults aged 50 and older with a systolic of 130 mmHg or higher and at least one additional risk factor, excluding patients with diabetes and prior stroke. One group was treated to a target below 140 mmHg, the conventional goal at the time. The other was treated to a target below 120. At one year the standard group averaged 136.2 mmHg systolic and the intensive group 121.4, a roughly 15-mmHg separation, sustained.

The primary outcome, a composite of myocardial infarction, acute coronary syndrome, stroke, heart-failure hospitalization, and cardiovascular death, occurred in 1.65% per year of the intensive group versus 2.19% of the standard group. The hazard ratio was 0.75: a 25% relative reduction, p < 0.001, with a 95% confidence interval (0.64 to 0.89) that didn’t come close to crossing one. All-cause mortality showed a hazard ratio of 0.73, a 27% relative reduction in death from any cause (95% CI 0.60 to 0.90, p = 0.003). The number needed to treat to prevent one primary event was 61; to prevent one death, 90.

Those are large effect sizes for a cardiovascular trial, and they’re why the safety board halted it early. A couple of caveats shape how to apply it to a younger reader. SPRINT’s readings were taken by an automated device after five minutes of rest, alone in the room, which reads several millimeters lower than a typical office cuff slapped on mid-conversation. So a SPRINT target of “below 120” corresponds to something more like “low 130s” in casual office settings, the same range we’re talking about for the borderline patient. SPRINT also excluded diabetes and prior stroke, and serious adverse events like syncope and acute kidney injury were more frequent in the intensive arm, which is exactly why treatment intensity belongs in the clinical encounter, not a blog post. But the central finding survives all of it: lowering pressure earlier and harder, in a high-risk middle-aged population, cut events by a fourth and death by more than a fourth.

The Read The running total isn’t only descriptive; SPRINT shows it bends. Lower the pressure earlier and the events and the deaths actually fall. The start date is part of the dose.

---

The million-adult dose-response

If SPRINT is the trial, Lewington 2002 is the field map. Published in The Lancet, it pooled individual data from sixty-one cohort studies, more than one million adults and around twelve million person-years of follow-up.² It remains the most widely cited estimate of dose-response in the field.

The finding belongs at the center of every “borderline” conversation. Across the systolic range of roughly 115 to 185 mmHg, in adults aged 40 to 69, each 20 mmHg rise in systolic (or 10 mmHg diastolic) was associated with roughly a doubling of mortality from both ischemic heart disease and stroke. The relationship was continuous and steadily rising all the way down, with no observable threshold above 115/75 below which it flattened.

This is what people miss when they hear “borderline.” They picture a soft category between “fine” and “high.” The Lewington data show no soft category. The difference between 116 and 136 systolic, sustained over decades, is the same shape of risk as the difference between 156 and 176. The artery doesn’t know “borderline” from “moderate hypertension” any more than the lung knows “social smoker” from “pack-a-day.” It just adds up the exposure.

---

CARDIA: real-time confirmation in young arteries

Lewington gives the dose-response across the broad adult population. CARDIA, the Coronary Artery Risk Development in Young Adults study, anchors it in a younger cohort with continuous longitudinal data, enrolling adults aged 18 to 30 in 1985 and 1986 and following them for decades.

When investigators computed each participant’s area under the systolic curve from young adulthood forward and tracked events into midlife, the pattern paralleled Lewington in an older population.⁵ Higher cumulative exposure in young adulthood was associated with later heart failure, coronary disease, stroke, and overall cardiovascular events, and the relationship held even after adjusting for the blood pressure at the time of the event. In plain terms: take two participants who reach midlife with the same current blood pressure, and the one whose accumulated exposure was higher carries the higher risk. The running total matters after controlling for the snapshot. That is exactly what the snapshot framework can’t account for.

---

What this means for a 35-year-old at 132/85

Let me run the math three ways for a thirty-five-year-old whose systolic has averaged around 134 mmHg since their early twenties, using 120 as the reference and counting excess mmHg-years above it. Same structural exercise I used for cumulative LDL in last week’s chapter.

Both lumens are still open. The point isn’t a sudden blockage. It’s the quieter difference the cuff can’t show: years of extra mechanical load on a living vessel wall. Schematic, not diagnostic.

Case A. Systolic has averaged 134 since age 20. Excess above the 120 reference: 14 mmHg. By age 35 they’ve banked 15 × 14 = 210 excess mmHg-years. If nothing changes, by 45 they reach 350, and by 65, 630.

Case B. Same start, but at age 30 they (or their physician) take it seriously, and lifestyle plus medication if needed brings the sustained systolic to the 120 reference. By 45 their cumulative excess is 10 × 14 (ages 20 to 30) + 15 × 0 = 140 excess mmHg-years, and it stays 140 at 65. The meter stopped the day the pressure came back to baseline. Relative to Case A, they’ve avoided 490 excess mmHg-years of wall stress by 65.

Case C. Same person, acting at 35 instead of 30. Cumulative excess by 45 is 15 × 14 = 210, holding at 210 by 65. The five-year delay costs about 70 excess mmHg-years locked in for life, and the savings compound with every additional decade above baseline avoided.

These numbers are illustrative, not prescriptive. Real blood pressure doesn’t sit flat; it drifts with age, stress, weight, sleep, training, and sodium. Pick 115 as the reference instead of 120 and every number gets larger. But the direction is right, the magnitudes are plausible, and the lesson is the one cholesterol taught too: the timeline of your pressure isn’t a backdrop to your risk. Once you’re above the line, it’s the primary driver.

The math your physician probably hasn’t done with you is this. At thirty-five, a low-grade hypertensive reading isn’t a holding pattern. It’s an unfolding excess, with a meter that’s been running since adolescence.

The Read A single 132/85 is not an emergency. Twenty years of 132/85 is a bill your arteries collect with interest. The cuff gives you a moment; the artery keeps the running total.

---

The 35-year window

Most cardiology risk calculators, including the new PREVENT score, estimate event probability over the next ten years. That’s useful for some decisions and deeply misleading for others. A thirty-five-year-old’s ten-year score almost always comes back low, because the next ten years genuinely don’t carry much absolute risk. The score isn’t broken; it’s doing its job. But the next thirty years, where Lewington and CARDIA both say the most damage compounds, aren’t on its clock.

So the right question for a thirty-five-year-old isn’t “what’s my ten-year risk?” It’s “what’s my thirty-year exposure trajectory, and what’s the leverage of intervening now versus in fifteen years?” SPRINT and the cumulative-exposure literature both answer: substantial. This is the leverage window, and it’s also the window where most people with low-grade readings do nothing, because the calculator tells them they don’t have to. The 2025 guideline is the first major U.S. document to push the other way, recommending medication for stage-1 patients whose pressure stays elevated after a serious lifestyle attempt, even at low ten-year risk. The framework is finally catching up to the cumulative reality.

---

The artery wall is alive, and we’ll come back to that

A note on what “wall stress” means at the cellular level, because the math can sound abstract.

The inner lining of every artery is a single layer of cells, the endothelium. It is not a passive surface. It senses pressure, flow, and chemical signals continuously, and it regulates tone, permeability, clotting, immune-cell adhesion, and the production of a key signaling molecule called nitric oxide. Expose that layer to higher mechanical stress over years and its signaling biology starts to change. The protective phenotype that keeps the wall calm and non-adhesive begins to erode, most readily where the artery’s geometry creates disturbed flow, particularly at the branch points where one vessel splits into two.

Branch points are where flow becomes complicated. Over time, pressure, shear, cholesterol, and inflammation converge on the same living surface: the endothelium.

That biology is the through-line connecting borderline blood pressure to borderline cholesterol to subclinical inflammation to early plaque. It’s the engine of everything the cardiac story turns toward over the next several posts, and it deserves its own chapter with the mechanism walked through carefully rather than waved at. For now, the through-line is enough: the wall is alive, the pressure is doing real work on it every minute of every year, and the running total of that work is what eventually shows up on a CT angiogram.

---

What I’m telling people in their thirties and forties

Three things, in practical terms.

Measure with a home cuff, not just at the office. A single office reading is a sample size of one, taken under conditions that bias the result, usually upward. A validated upper-arm cuff used at home over a few weeks, with proper technique (seated, back supported, feet flat, arm at heart level, after several minutes of rest, two readings a minute apart, twice a day for a week), is the standard the 2025 guideline now formally endorses for diagnosis.³ A home average is what you should track, not a clinic snapshot. One honest caveat: a brachial cuff measures peripheral pressure, the pressure in your upper arm. The pressure that matters most to your heart, brain, and kidneys is central pressure, at the aortic root, and the two can diverge with age and arterial stiffening. That’s a layer of resolution worth knowing about, and a topic for a future post.

Reframe the question from “is my reading borderline?” to “what’s my mmHg-years trajectory?” The first gets a snapshot answer. The second forces a conversation about time. Ask a primary-care physician, “what does my cumulative exposure look like over the next twenty years if we don’t change anything?” and you’ve moved the dialogue from one inflection point to a curve, even with a physician who has never thought in mmHg-years.

If your reading has been in the low 130s or upper 80s for a decade, that’s not a snapshot. That’s data. Bring the time series. Ten readings of 132/85 over fifteen years isn’t “borderline.” It’s a confirmed exposure pattern. Your physician’s instinct will be to look at the most recent point; the instinct that serves you, the same one I learned when I had to fight for the right cardiac scan, is to show them the full picture and ask for what it warrants.

---

If your reading is in stage 1, here’s what to do this week

Future posts will go deep on the specific things that move cumulative blood pressure. For now, the foundations. None of this substitutes for the conversation with your own physician; treat them as the conversation starters worth raising at your next visit.

• Ask about a confirmed home-cuff average. This is the conversation the 2025 guideline tells your physician to have with you. Ten readings a week, taken correctly, for a month is enough to land an honest baseline.
• If you smoke, this is the single highest-leverage change you can make. Nothing else is close. Pack-years compound the same way mmHg-years do, and quitting moves the curve faster than any other lever.
• If you don’t have a structured exercise routine, start one. Most-days brisk walking plus a couple of strength sessions a week moves blood pressure and a long list of downstream variables. Next week’s post on cardiovascular training goes deeper.
• If you snore loudly, gasp awake, or wake up unrefreshed, ask about obstructive sleep apnea. Untreated OSA pushes blood pressure up overnight, and a meaningful share of “treatment-resistant” hypertension is undiagnosed OSA.
• If you carry excess weight, particularly around the midsection, losing it reliably moves the number, especially paired with the changes above. Five to ten percent of body weight is roughly where the response becomes measurable on a home cuff.

---

What I Changed

This is what changed for me, offered as my read of the evidence and my own situation, not a prescription for yours.

I stopped treating the office reading as the number. One cuff in a bright room, taken after the waiting-room rush, is a sample of one, and usually a biased one. The number I track now is a home-cuff average over time.

I started thinking in trajectories instead of snapshots: not “is today’s reading borderline,” but “what does my mmHg-years curve look like over the next twenty years if nothing changes.” And I bring that time series into the room instead of accepting the single most recent dot. The version of me at thirty could have bent that curve for the price of a conversation. He never had it.

---

The Calibrated Claim Audit

Claim	Mechanism strength	Evidence quality	My read
A single office reading tells you your blood-pressure risk.	Weak	Weak for individual trajectory	It’s a sample of one, not the signal.
Chronically elevated blood pressure damages arteries over time.	Very strong	Very strong: million-adult dose-response, decades of cohorts, a randomized trial	High confidence. The artery logs every reading.
Lowering sustained pressure earlier reduces events.	Very strong	Strong randomized evidence (SPRINT) in higher-risk adults	The direction is settled; the intensity is individualized.

Commercial distortion risk: Low. This is foundational cardiovascular physiology, not a supplement sector. The distortion here isn’t a product being sold. It’s clinical inertia: a system that measures a continuous signal once a year and treats anything short of stage 2 as discretionary.

---

What’s next, and where we’re heading

The cumulative-exposure framework I walked through for LDL and now for blood pressure isn’t a coincidence. It’s the same idea applied to two inputs. Both add up over decades, both do most of their damage between snapshots, and both are largely modifiable above a sensible reference.

Next week I want to step away from lab values and toward the way I trained my body for thirty years, the next crack in the list I named a few weeks ago. I trained for the mirror. I didn’t train for the running total. The literature on what aging-adapted cardiovascular training actually looks like has gotten clearer in the last decade, and that’s the chapter I want next.

One last thing. Across the next several posts you’ll see me reach for a framework called the hallmarks of aging: the molecular and cellular processes biologists now think drive aging itself, first laid out by Carlos López-Otín and colleagues in 2013 and expanded in 2023 to twelve interlinked hallmarks.⁴ I’m going to start anchoring health concepts back to which hallmark they touch, because that’s the lens through which I now think about every intervention. Borderline blood pressure isn’t just a cardiology story. In my reading it intersects altered intercellular communication, chronic inflammation, and mitochondrial dysfunction in the vessel wall, among others. We’ll trace those out as we reach each one.

---

The Final Signal

• What this gets right. Blood pressure is a moving signal, and a single office reading is a weak sample of it. Repeated, validated home measurement is the honest baseline, and the 2025 AHA/ACC guideline now says so too.
• What gets missed. A “borderline” annual number can hide decades of excess mmHg-years. The damage compounds between the readings, where the snapshot model can’t see it.
• What I changed. I stopped treating the office number as the number. I track a home-cuff average and the trajectory, and I bring the time series into the clinician conversation.
• What not to overclaim. One reading isn’t destiny, and low blood pressure has a real danger floor; the relationship is J-shaped, not a straight line to zero. The goal is excess mmHg-years above a sensible reference, not the lowest possible number.
• What this opens next. The artery wall is alive. Blood pressure is where the endothelium, nitric oxide, and the earliest plaque all connect, the through-line the next several posts trace, and the first place the hallmarks-of-aging lens earns its keep.

---

References

1. The SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373(22):2103-2116. PMID: 26551272 [Finding: In 9,361 higher-risk adults over 50, a systolic target below 120 instead of below 140 cut major cardiovascular events by 25% and deaths by 27%. The trial was stopped early.]

2. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903-1913. PMID: 12493255 [Finding: Across more than a million adults in 61 cohorts, the link between usual blood pressure and vascular death was continuous down to 115/75, with each 20 mmHg systolic (or 10 mmHg diastolic) roughly doubling the risk. No threshold.]

3. Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension. 2025;82(10):e212-e316. PMID: 40811516 [Finding: The current U.S. guideline reclassifies 130/80 and up as Stage 1 hypertension, adopts the PREVENT risk calculator, lowers the bar to start medication in younger adults, and endorses validated home-cuff measurement for diagnosis.]

4. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell. 2023;186(2):243-278. PMID: 36599349 [Finding: The 2023 update to the hallmarks-of-aging framework, naming twelve interlinked processes that drive aging, including altered intercellular communication and chronic inflammation.]

5. Nwabuo CC, Appiah D, Moreira HT, et al. Long-term cumulative blood pressure in young adults and incident heart failure, coronary heart disease, stroke, and cardiovascular disease: The CARDIA study. Eur J Prev Cardiol. 2021;28(13):1445-1451. PMID: 34695218 [Finding: In adults tracked from young adulthood, higher cumulative blood-pressure exposure predicted later heart failure, coronary disease, and stroke, adding prognostic value beyond any single reading.]

6. Reges O, Ning H, Wilkins JT, et al. Association of Cumulative Systolic Blood Pressure With Long-Term Risk of Cardiovascular Disease and Healthy Longevity: Findings From the Lifetime Risk Pooling Project Cohorts. Hypertension. 2021;77(2):347-356. PMID: 33342241 [Finding: Across five diverse U.S. cohorts, higher cumulative systolic exposure predicted more cardiovascular events and an earlier age of onset, even after accounting for blood pressure measured at a single point.]